Exelixis, Inc. (EXEL) fair value analysis

Nasdaq · Updated 2026-09-07

Exelixis, Inc. is a biopharmaceutical company that develops and commercializes oncology medicines, focusing on treatments for various types of cancer. The company operates in the United States and internationally, conducting research, development, and sales activities across multiple markets.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, EXEL is trading at a 10–25% discount to estimated fair value.

EXEL currently ranks #46 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $55.06
Sector: Healthcare
12-month range: $38.06–$55.06

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Low
Margin trend: Stable
Revenue growth: Strong
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The top quarter of its range
DCF cross-check: Undervalued

What our data shows for EXEL

Our model validated 17 trailing price-to-earnings windows for EXEL, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $38.06–$55.06.
The 14-day relative strength index sits at a neutral 58.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for EXEL
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent EXEL news

TickrTrends' derived news-sentiment signal for EXEL is currently leaning positive, computed from recent coverage.

Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript (seekingalpha.com, 2026-09-08)
TickrTrends take: Exelixis presented at the Wells Fargo Healthcare Conference, providing investors with updates on the company's pipeline and business strategy. Given TickrTrends' current undervalued assessment, presentation commentary regarding revenue drivers, clinical progress, or market expansion could be material for investors monitoring whether the company's fundamentals justify a higher valuation multiple. Valuations in the healthcare sector often reflect pipeline strength and commercial execution, making conference disclosures particularly relevant to reassessing price targets.
EXEL Looks 18.3% Overvalued on GF Value™ After Patent Win (gurufocus.com, 2026-08-31)
TickrTrends take: TickrTrends' current assessment of EXEL as undervalued stands in contrast to the GF Value™ analysis suggesting the stock is overvalued following the patent win announcement. The divergence between these valuation frameworks highlights the importance of monitoring how the market prices in the intellectual property victory relative to fundamental metrics. For valuation-focused investors, reconciling these opposing signals will depend on whether EXEL's patent success translates into sustained competitive advantages and earnings growth that justify current or higher price levels in the Healthcare sector.
Exelixis, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EXEL) 2026-08-06 (seekingalpha.com, 2026-08-06)
TickrTrends take: Exelixis released its second quarter 2026 results, providing updated financial and operational metrics that inform assessments of the company's current market valuation. TickrTrends' analysis currently indicates the stock is undervalued within the Healthcare sector, suggesting investors monitoring this earnings presentation should examine whether the company's recent performance and guidance support or challenge this valuation stance. The earnings call materials offer concrete data points for evaluating whether EXEL's market price appropriately reflects its underlying business fundamentals and future prospects.

What people are saying

Follow the EXEL conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — TickrTrends' derived indicators for EXEL show a shift in valuation assessment this week. The DCF cross-check band moved from a fairly valued position to undervalued, aligning with the current undervalued verdict for the Healthcare sector company.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is EXEL stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), EXEL is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is EXEL's TickrTrends verdict?

EXEL's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does EXEL compare to other Healthcare stocks?

EXEL ranks #46 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is EXEL overbought or oversold?

EXEL's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

EXEL vs BTSG · EXEL vs COLL · EXEL vs DVA · EXEL vs EW · EXEL vs GMAB